Sign in Sign up for free

Last updated: 2 April 2021 at 1:30pm EST

Matthew Emmens Net Worth




The estimated Net Worth of Matthew Emmens is at least $13.7 Million dollars as of 6 February 2012. Mr. Emmens owns over 56,000 units of Bristol-Myers Squibb Co stock worth over $10,281,693 and over the last 19 years he sold BMY stock worth over $3,109,166. In addition, he makes $354,808 as Independent Director at Bristol-Myers Squibb Co.

Mr. Emmens BMY stock SEC Form 4 insiders trading

Matthew has made over 3 trades of the Bristol-Myers Squibb Co stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 56,000 units of BMY stock worth $2,115,680 on 6 February 2012.

The largest trade he's ever made was selling 56,000 units of Bristol-Myers Squibb Co stock on 6 February 2012 worth over $2,115,680. On average, Matthew trades about 1,964 units every 7 days since 2005. As of 6 February 2012 he still owns at least 211,601 units of Bristol-Myers Squibb Co stock.

You can see the complete history of Mr. Emmens stock trades at the bottom of the page.





Matthew Emmens biography

Matthew W. Emmens serves as Independent Director of the Company. Mr. Emmens Served as Chief Executive Officer of Shire PLC from 2003 until 2008 and Chairman of the Board from 2008 until 2014. He also served as a Director of Vertex Pharmaceuticals Incorporated from 2004 until 2009, Chairman, President and Chief Executive Officer from 2009 until 2012 and Director from 2012 until 2013. Mr. Emmens served as President, Worldwide Pharmaceuticals of Merck KGaA from 1999 until 2003, as Chief Executive Officer, Commercial Operations of Astra Merck Inc. from 1992 until 1999 and in Sales, Marketing and Administration positions for Merck & Co., Inc. from 1974 until 1991.

What is the salary of Matthew Emmens?

As the Independent Director of Bristol-Myers Squibb Co, the total compensation of Matthew Emmens at Bristol-Myers Squibb Co is $354,808. There are 12 executives at Bristol-Myers Squibb Co getting paid more, with Giovanni Caforio having the highest compensation of $18,767,300.



How old is Matthew Emmens?

Matthew Emmens is 68, he's been the Independent Director of Bristol-Myers Squibb Co since 2017. There are 1 older and 35 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.

What's Matthew Emmens's mailing address?

Matthew's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, 430 E. 29TH STREET, 14 FLOOR, NEW YORK, NY, 10016.

Insiders trading at Bristol-Myers Squibb Co

Over the last 16 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius, and Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.



What does Bristol-Myers Squibb Co do?

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.



What does Bristol-Myers Squibb Co's logo look like?

Bristol-Myers Squibb Co. logo

Complete history of Mr. Emmens stock trades at Incyte, Vertex Pharmaceuticals, and Bristol-Myers Squibb Co

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
6 Feb 2012 VRTX Vertex Pharmaceuticals, Inc. Matthew Emmens
Director
 Sale 56,000 $37.78 $2,115,680
6 Feb 2012
211,601 ↗
16 Nov 2011 VRTX Vertex Pharmaceuticals, Inc. Matthew Emmens
Director
 Sale 10,850 $41.76 $453,096
16 Nov 2011
200,873 ↗
25 May 2011 VRTX Vertex Pharmaceuticals, Inc. Matthew Emmens
Director
 Sale 9,735 $55.51 $540,390
25 May 2011
220,400 ↗


Bristol-Myers Squibb Co executives and stock owners

Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include: